Cargando…

Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors

INTRODUCTION: Oral antidiabetes medications, including dipeptidyl peptidase-4 inhibitors (DPP-4is) saxagliptin and sitagliptin, are used for the treatment of type 2 diabetes (T2D). The study objective was to compare all-cause and diabetes-related costs following initiation of saxagliptin or sitaglip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farr, Amanda M., Sheehan, John J., Brouillette, Matthew, Smith, David M., Johnston, Stephen S., Kalsekar, Iftekhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735222/ https://www.ncbi.nlm.nih.gov/pubmed/26724938 http://dx.doi.org/10.1007/s12325-015-0277-2

Ejemplares similares

Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus
por: Farr, Amanda M., et al.
Publicado: (2014)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population
por: Kalsekar, Iftekhar, et al.
Publicado: (2006)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders, William B, et al.
Publicado: (2016)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

Improving visual communication of discriminative accuracy for predictive models: the probability threshold plot
por: Johnston, Stephen S, et al.
Publicado: (2021)

Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes
por: Kheloussi, Steven, et al.
Publicado: (2021)

Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy
por: Nadkarni, Anagha, et al.
Publicado: (2013)

Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2015)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
por: Charokopou, M., et al.
Publicado: (2015)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Evaluation of the University of California Diabetes Prevention Program (UC DPP) Initiative
por: Gholami, Maryam, et al.
Publicado: (2021)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
por: Nag, Snehasish, et al.
Publicado: (2023)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

The impact of an immunization training certificate program on the perceived knowledge, skills and attitudes of pharmacy students toward pharmacy-based immunizations
por: Marcum, Zachary A., et al.
Publicado: (2010)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
por: Choe, Eun Yeong, et al.
Publicado: (2014)

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2022)

Real-world outcomes comparison among adults with atrial fibrillation undergoing catheter ablation with a contact force porous tip catheter versus a second-generation cryoballoon catheter: a retrospective analysis of multihospital US database
por: Costea, Alexandru, et al.
Publicado: (2020)

Association of tumor location with economic outcomes and air leak complications in thoracic lobectomies: results from a national hospital billing dataset
por: Bhora, Faiz, et al.
Publicado: (2019)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Assessment of obesity prevalence and validity of obesity diagnoses coded in claims data for selected surgical populations: A retrospective, observational study
por: Ammann, Eric M., et al.
Publicado: (2019)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

The direct and indirect costs of adult atopic dermatitis
por: Manjelievskaia, Janna, et al.
Publicado: (2021)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
por: Thomas, Merlin C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_49oj4m95tio8brl2s0ilt1mfj7